Clinical trial

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

NCT02125240

Study summary

ClinicalTrials.gov

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Icotinib Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2014-09-01

PhasePHASE3

Conditions

EGFR Positive Non-small Cell Lung Cancerunresolved

Adenocarcinomaverified · MONDO: adenocarcinoma

Interventions

IcotinibDRUG

PlaceboDRUG

Sponsors & collaborators

Betta Pharmaceuticals Co., Ltd.lead sponsor

Mapped research locations

BeijingBeijing Municipality, China11

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02125240 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.